What does Accuray Incorporated do?
Accuray Incorporated is a Madison, Wisconsin-based radiation therapy company listed on Nasdaq as ARAY. It designs, manufactures, sells, and supports precision systems used by hospitals and cancer centers to treat tumors throughout the body. Its model is specialized medical technology: capital equipment, software, upgrades, and multi-year service support.
Which product platforms define the company?
Accuray’s mission is to expand the curative power of radiation therapy. Commercially, that means competing on precision, workflow, reliability, and complex-case capability. The official company overview frames this strategy around personalized treatment and patient outcomes.
Why does Accuray matter in radiation oncology?
Accuray offers an alternative to conventional gantry-based linear accelerators. CyberKnife provides robotic delivery, while TomoTherapy and Radixact use helical delivery with integrated imaging. These platforms address motion, irregular anatomy, retreatment, stereotactic radiosurgery, and high-volume workflows. Although Accuray is smaller than the leaders, its installed base supports service revenue, clinical familiarity, and upgrades.
How does Accuray make money?
Accuray has two revenue engines. Product revenue comes from systems, upgrades, options, and equipment. Service revenue comes from maintenance, parts, training, and support. System sales are larger and less predictable; service contracts monetize the installed base over time.
How do product and service economics differ?
| Revenue stream | FY2025 revenue | How it is earned | Analytical implication |
|---|---|---|---|
| Products | $237.6M | System shipments, upgrades, options, and accessories; revenue depends on delivery, installation, acceptance, and contract terms. | Creates growth and expands the future service base, but timing is lumpy and exposed to hospital capital budgets, permits, site readiness, and logistics. |
| Services | $220.9M | Maintenance contracts, parts, training, and support recognized over contractual service periods. | More recurring and resilient, but profitability depends on field efficiency, parts consumption, uptime obligations, and the age of the installed base. |
| Orders and backlog | $288.0M gross orders | Signed product orders enter backlog after defined criteria; FY2025 net orders were $177.2M after age-outs and cancellations. | Backlog is an indicator, not guaranteed revenue. Conversion timing and order quality are more useful than the headline balance alone. |
What does the geographic model add?
Accuray sells directly and through distributors. International distributors generated 81% of FY2025 gross orders, up from 74% in FY2024, lowering fixed commercial needs but increasing channel risk. In China, Accuray Asia owns 49% of a joint venture controlled 51% by China Isotope & Radiation Corporation. It manufactures and sells Tomo C and buys products and services from Accuray.
The FY2025 Form 10-K is the primary source for the company’s product, service, geographic, distributor, joint-venture, and risk disclosures.
Which turning points shaped Accuray’s current strategy?
Accuray combines two technology lineages: robotic radiosurgery and helical radiation therapy. Its strategic challenge is converting differentiated engineering into a broader, more predictable, profitable platform.
-
Early 1990sThe first CyberKnife implementation established robotic radiation delivery as Accuray’s foundational capability. The platform’s history remains important because motion tracking and robotic beam geometry still distinguish the company.
-
2001U.S. clearance expanded CyberKnife treatment beyond intracranial applications to tumors throughout the body, widening the addressable clinical market and linking the platform to stereotactic body radiation therapy.
-
2011Accuray completed the TomoTherapy acquisition after announcing an approximately $277M cash-and-stock transaction. The deal added helical radiation therapy, a larger installed base, and a substantial service operation.
-
2016The Radixact platform received U.S. clearance, modernizing the TomoTherapy architecture and creating the base for later imaging, synchronization, planning, and adaptive-workflow improvements.
-
2019The 49%-owned China joint venture was formed to localize manufacturing and commercial access. It created a path into China’s Class B market, but also introduced partner, policy, sanctions, data, and payment exposure.
-
2023–2025Chinese regulatory approvals accumulated for Tomo C, planning software, Radixact SynC, and CyberKnife S7. These approvals supported localization but did not remove the volatility of government purchasing and installation timing.
-
2025Accuray launched Stellar and initiated a broad transformation plan. The product move aimed to strengthen mainstream competitiveness; the operating move targeted approximately $25M of annualized profit improvement.
-
2026A ten-year research agreement with the University of Wisconsin-Madison extended the company’s adaptive-radiotherapy development network and reconnected commercial product development with the academic roots of helical therapy.
Why does the TomoTherapy acquisition still matter?
The 2011 combination changed Accuray from a company centered mainly on CyberKnife into a two-platform radiation oncology supplier. The official acquisition announcement said the installed base increased from 226 to more than 550 systems in 32 countries. That expansion explains why service revenue is now nearly half of sales and why field support, spare parts, uptime, and installed-base retention are as important as new system innovation.
What does Accuray’s latest reported quarter show?
The latest official period is Q3 FY2026, ended March 31, 2026. Service was relatively stable, revenue improved sequentially, and underlying costs fell, but product demand, margin, backlog, liquidity, and reported profit remained pressured.
Which figures explain the quarter?
| Metric | Q3 FY2026 | Prior-year Q3 | Interpretation |
|---|---|---|---|
| Product revenue | $49.7M | $57.3M | A 13% decline reflected lower shipment volume and continued volatility in system timing. |
| Service revenue | $55.1M | $55.9M | Only a 1% decline, reinforcing the recurring value of the installed base. |
| Gross profit | $25.3M | $31.6M | Higher net parts consumption of $3.2M plus elevated logistics and duties compressed margin. |
| Operating expenses | $34.4M | $30.6M | The quarter included $6.5M of restructuring charges; excluding them, expenses fell 9% year over year. |
| Diluted EPS | -$0.09 | -$0.01 | Restructuring, weak gross profit, and interest expense outweighed cost actions. |
Accuray’s Q3 FY2026 earnings release reported approximately $10M of cost and margin improvement through the quarter. Management also withdrew full-year revenue and adjusted EBITDA guidance because Middle East geopolitical uncertainty affected installation timing.
Is sequential revenue improvement enough?
Why do service revenue and backlog matter so much?
A few delayed installations can move quarterly revenue sharply. Service and backlog help separate installed-base economics from shipment timing, but neither is mechanically predictive.
How resilient is the service base?
Service stabilized revenue during a weak equipment cycle, but higher parts and logistics costs show that recurring revenue is not automatically high-margin. Monitor service gross margin, renewals, uptime, and installed-base age.
What does backlog quality reveal?
Backlog fell roughly $70.7M over nine months. FY2025 included $125.5M of age-outs, $25.8M of age-ins, and $7.7M of cancellations, showing why headline backlog needs judgment. Analyze gross and net orders, book-to-bill, cancellations, age-outs, distributor mix, and conversion to product revenue together.
The detailed March 2026 Form 10-Q provides the latest balance-sheet, cash-flow, geographic, debt, restructuring, and joint-venture disclosures behind these operating indicators.
Robotic and helical radiotherapy define Accuray’s competitive position
Accuray competes in a concentrated medical-device market against Varian, part of Siemens Healthineers, Elekta, RefleXion, and Zap Surgical. Its filing says Varian holds a majority global share. That scale gap affects product breadth, sales coverage, service density, research budgets, and customer risk perception.
What creates genuine differentiation?
CyberKnife’s robotic geometry and motion management are difficult to reproduce as a conventional add-on. Radixact creates a different helical workflow. Training, planning, quality assurance, protocols, facility layout, and service integration add switching costs. These resources support a defensible niche, not broad dominance.
Where does the competitive model remain vulnerable?
| Competitive factor | Accuray position | Pressure from rivals | What would strengthen the position |
|---|---|---|---|
| Precision and motion management | CyberKnife is meaningfully differentiated. | Alternative stereotactic systems and improved conventional linacs can address overlapping cases. | Clinical evidence, easier workflow, faster treatment, and consistent outcomes. |
| Mainstream department workflow | Radixact and Stellar broaden relevance. | Varian and Elekta have greater breadth, scale, and installed-base reach. | Adaptive capability that is practical for departments of different sizes. |
| Service and reliability | Recurring service base and specialized expertise. | Parts use, downtime, and field costs can weaken customer economics and margin. | Higher uptime, lower parts intensity, remote support, and better logistics. |
| Commercial reach | Global presence with extensive distributors. | Distributor dependence can reduce control over pipeline quality and installations. | Sharper channel management, reference sites, and focused geographic execution. |
How financially strong is Accuray?
Accuray entered FY2026 with modest operating profit, thin cash generation, substantial debt, and limited equity. The first nine months weakened that profile, making liquidity more sensitive to orders, installation timing, service margin, and working capital.
What changed from FY2025 to March 2026?
| Financial signal | FY2025 or June 30, 2025 | Nine months or March 31, 2026 | Interpretation |
|---|---|---|---|
| Revenue | $458.5M | $301.0M | The nine-month figure was down 9% year over year, driven by a 21% product decline. |
| Gross margin | 32.1% | 25.4% | Product mix, service costs, logistics, duties, and lower volume reduced conversion of revenue into gross profit. |
| Operating result | $7.8M income | $32.0M loss | FY2026 includes $15.4M of restructuring charges through Q3, but weak gross profit remains the larger issue. |
| Operating cash flow | $2.9M | -$9.4M | Inventory growth and losses absorbed cash; inventory used $20.6M through the first nine months. |
| Cash and restricted cash | $62.1M | $44.4M | Liquidity declined despite financing inflows, increasing the importance of working-capital and order conversion. |
| Stockholders’ equity | $81.2M | $41.7M | Losses and financing effects reduced the residual equity cushion. |
What do margin, debt, and cash flow imply?
The June 2025 refinancing included a $120M term loan A, $30M term loan B, $20M delayed-draw facility, and $20M revolver. On June 1, 2026, Accuray repaid the remaining $18M convertible notes in full, plus $0.3M of accrued interest. Secured debt, interest, covenants, and collateral still constrain flexibility.
Who owns Accuray, and how does governance shape decisions?
Accuray has one common class with one vote per share and no founder dual-class control. Ownership is dispersed, but the 2025 refinancing gave TCW influence beyond its economic stake.
Which ownership facts matter most?
| Holder or group | Beneficial ownership | Source period | Governance relevance |
|---|---|---|---|
| TCW Group | 11.9M shares, 10.6% | 2025 proxy, based on June 6, 2025 reporting | Ownership was reported through financing warrants; TCW also received board designation and observer rights. |
| BlackRock | 6.7M shares, 6.0% | 2025 proxy | A significant passive institutional position, but without special voting control disclosed in the proxy. |
| Directors and current executive officers as a group | 5.0M shares, 4.36% | 2025 proxy; 15 persons | Creates economic alignment, though the group does not control the vote. |
| Shares outstanding | 112.7M shares | August 31, 2025 | Provides the denominator for proxy ownership; shares rose to 118.9M by March 31, 2026. |
These figures come from the 2025 definitive proxy statement. The proxy also reported 93.2% support for the prior annual say-on-pay vote, suggesting no broad shareholder rejection of the compensation framework at that time.
How have leadership and lender influence changed?
Steve La Neve became CEO in October 2025 after more than forty years in medical technology. The board named TCW-designated director Steven F. Mayer Transformation Board Sponsor, reinforcing an agenda of cost discipline, commercial improvement, and debt protection.
Transformation oversight can accelerate decisions and accountability. Yet a secured lender with board access may emphasize liquidity, covenants, and debt repayment. The current board roster is therefore relevant to interpreting strategy, not merely a governance formality.
China, Stellar, and the transformation plan define the forward case
Accuray’s forward case rests on three linked questions: can China stabilize, can Stellar widen the market, and can restructuring improve profit without damaging sales or technology? Product relevance, order quality, margin, and liquidity must reinforce one another.
Where could growth and margin improve?
The Stellar launch adds an all-in-one Radixact configuration. The test is whether its clinical and workflow benefits change hospital purchasing against larger incumbents.
What risks could weaken the outlook?
| Risk | Transmission to financial results | Evidence to monitor |
|---|---|---|
| Weak product orders | Reduces future installations, product revenue, installed-base growth, and eventual service revenue. | Gross orders, book-to-bill, backlog, age-outs, cancellations, and distributor order share. |
| Gross-margin pressure | Higher parts, freight, tariffs, duties, and unfavorable mix can erase gains from operating-cost reductions. | Product and service gross margin, parts consumption, logistics cost, and warranty trends. |
| China joint-venture exposure | Policy changes, sanctions, data rules, partner incentives, receivables, and procurement timing can affect revenue and cash. | China revenue, joint-venture receivables, regulatory approvals, local production, and payment collection. |
| Debt and covenant risk | Interest and secured-credit obligations reduce strategic flexibility and raise the cost of a prolonged downturn. | Cash, revolver availability, net leverage, interest expense, covenant amendments, and debt maturities. |
| Transformation execution | Workforce reductions and outsourcing may lower cost but can disrupt sales, development, service quality, or employee retention. | Savings realized, restructuring charges, service performance, R&D output, and order momentum. |
| Internal-control remediation | Material weaknesses can increase reporting risk and consume management attention. | Remediation progress, amended filings, audit conclusions, and disclosure controls. |
The December 2025 transformation plan affected about 15% of employees and targeted $25M of annualized operating-profit improvement, showing both opportunity and urgency.
Which variables matter most in valuation?
A DCF should not treat either FY2025 operating margin or the Q3 FY2026 loss as normalized. Build scenarios around orders, conversion, service retention, gross-margin recovery, restructuring, working capital, and financing. At Accuray’s scale, a few margin points can materially change free cash flow.
What is the key takeaway from Accuray analysis?
Accuray offers differentiated robotic and helical radiation therapy in a market dominated by larger vendors. CyberKnife, Radixact, recurring service, international reach, and China localization are real assets. The challenge is converting them into consistent orders, healthy margin, positive free cash flow, and a durable capital structure.
Accuray is a useful case in resource advantage, medical-device regulation, installed-base economics, channel governance, and turnaround strategy. Monitor product orders, backlog quality, geographic conversion, service margin, transformation savings, cash flow, and liquidity together. That combination will show whether Accuray is becoming a stronger operating company, not merely a distinctive technology company.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.